Osteoporosis risk assessment using multilayered gold-nanoparticle thin film via SALDI-MS measurement

  • Xi-Yu Pan
  • Chih-Hwa Chen
  • Yi-Hsuan Chang
  • Di-Yan Wang
  • Yi-Cheng Lee
  • Chien-Chung Liou
  • Yu-Xian Wang
  • Cho-Chun Hu
  • Tsung-Rong KuoEmail author
Paper in Forefront


A powerful technique to detect bone biomarkers has been developed for assessment of osteoporosis at the early stage. Two-dimensional multilayered gold-nanoparticle thin film (MTF-AuNPs) was demonstrated as a promising test platform for detection of bone biomarker, hydroxyproline (HYP), measured by surface-assisted laser desorption/ionization mass spectrometry (SALDI-MS). With strong surface plasmon resonance and excellent homogeneity, facilely prepared, highly ordered, and large-scale MTF-AuNPs revealed high sensitivity of HYP in the SALDI-MS measurement without additional matrixes, such as α-cyano-4-hydroxycinnamic acid (CHCA) and 2,5-dihydroxybenzoic acid (DHB). Furthermore, the mass spectrum of HYP with MTF-AuNPs was significantly improved in signal intensity enhancement, background noise reduction, and signal-to-noise ratio amplification. The excellent reproducibility of HYP spectra with only 9.3% relative signal variation could be attributed to MTF-AuNPs’ high absorbance at a wavelength of 337 nm, low heat capacity, superior thermal conductivity, and outstanding homogeneity. The calibration curve showed high linear correlation between mass spectrum intensity and HYP concentration in the range of 1 to 100 μM, covering the whole level in healthy people and osteoporosis patients. In particular, the serum sample was directly deposited onto the MTF-AuNP sample substrate without any pretreatment and its HYP concentration was then successfully determined. We believe that the combination of SALDI-MS and MTF-AuNP sample substrates would be a potential approach for bone biomarker detection in the osteoporosis risk assessment.

Graphical abstract


Osteoporosis Biomarker Gold nanoparticles Multilayered thin film Sample substrate Serum 



We would like to acknowledge Mr. Chi-Ming Lee for his excellent technical support at TMU Core Facility.

Funding information

This work was supported by MOST 107-2113-M-038-004, MOST 105-2119-M-038-002-MY2, MOST 107-2622-E-038-001-CC2, and Taipei Medical University.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

216_2019_1759_MOESM1_ESM.pdf (1.2 mb)
ESM 1 (PDF 1215 kb)


  1. 1.
    Cummings SR, Melton Iii LJ. Osteoporosis i: epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–7.CrossRefGoogle Scholar
  2. 2.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637–45.CrossRefGoogle Scholar
  3. 3.
    Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–41.CrossRefGoogle Scholar
  4. 4.
    Klibanski A, Adams-Campbell L, Bassford T, Blair SN, Boden SD, Dickersin K, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95.CrossRefGoogle Scholar
  5. 5.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437–44.CrossRefGoogle Scholar
  6. 6.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.CrossRefGoogle Scholar
  7. 7.
    Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol Inflamm. 2017;4:46.CrossRefGoogle Scholar
  8. 8.
    Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, et al. Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop. 2016;7:171.CrossRefGoogle Scholar
  9. 9.
    Blake GM, Fogelman I. Role of dual-energy x-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom. 2007;10:102–10.CrossRefGoogle Scholar
  10. 10.
    Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (dexa). J Pediatr. 2004;144:253–7.CrossRefGoogle Scholar
  11. 11.
    Massie A, Reid DM, Porter RW. Screening for osteoporosis: comparison between dual energy x-ray absorptiometry and broadband ultrasound attenuation in 1000 perimenopausal women. Osteoporos Int. 1993;3:107–10.CrossRefGoogle Scholar
  12. 12.
    Kuo T-R, Chen C-H. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017;5:18.CrossRefGoogle Scholar
  13. 13.
    Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the intergroup exemestane study (ies): a randomised controlled study. Lancet Oncol. 2007;8:119–27.CrossRefGoogle Scholar
  14. 14.
    Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126–37.CrossRefGoogle Scholar
  15. 15.
    Lucas EA, Wild RD, Hammond LJ, Khalil DA, Juma S, Daggy BP, et al. Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab. 2002;87:1527–32.CrossRefGoogle Scholar
  16. 16.
    Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, et al. Effect of the cathepsin k inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase i studies. Clin Pharmacol Ther. 2009;86:175–82.CrossRefGoogle Scholar
  17. 17.
    Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol. 2012;8:379–89.CrossRefGoogle Scholar
  18. 18.
    Wang L, Hu YQ, Zhao ZJ, Zhang HY, Gao B, Lu WG, et al. Screening and validation of serum protein biomarkers for early postmenopausal osteoporosis diagnosis. Mol Med Rep. 2017;16:8427–33.CrossRefGoogle Scholar
  19. 19.
    Fink HA, Litwack-Harrison S, Taylor BC, Bauer DC, Orwoll ES, Lee CG, et al. Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the osteoporotic fractures in men (MrOS) study. Osteoporos Int. 2016;27:331–8.CrossRefGoogle Scholar
  20. 20.
    Jagtap VR, Ganu JV. Effect of antiresorptive therapy on urinary hydroxyproline in postmenopausal osteoporosis. Indian J Clin Biochem. 2012;27:90–3.CrossRefGoogle Scholar
  21. 21.
    Kuo T-R, Chen J-S, Chiu Y-C, Tsai C-Y, Hu C-C, Chen C-C. Quantitative analysis of multiple urinary biomarkers of carcinoid tumors through gold-nanoparticle-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chim Acta. 2011;699:81–6.CrossRefGoogle Scholar
  22. 22.
    Law KP, Larkin JR. Recent advances in SALDI-MS techniques and their chemical and bioanalytical applications. Anal Bioanal Chem. 2011;399:2597–622.CrossRefGoogle Scholar
  23. 23.
    Tang HW, Ng KM, Lu W, Che CM. Ion desorption efficiency and internal energy transfer in carbon-based surface-assisted laser desorption/ionization mass spectrometry: desorption mechanism(s) and the design of SALDI substrates. Anal Chem. 2009;81:4720–9.CrossRefGoogle Scholar
  24. 24.
    Watanabe T, Kawasaki H, Yonezawa T, Arakawa R. Surface-assisted laser desorption/ionization mass spectrometry (SALDI-MS) of low molecular weight organic compounds and synthetic polymers using zinc oxide (ZnO) nanoparticles. J Mass Spectrom. 2008;43:1063–71.CrossRefGoogle Scholar
  25. 25.
    Wu HP, Su CL, Chang HC, Tseng WL. Sample-first preparation: a method for surface-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of cyclic oligosaccharides. Anal Chem. 2007;79:6215–21.CrossRefGoogle Scholar
  26. 26.
    Su C-L, Tseng W-L. Gold nanoparticles as assisted matrix for determining neutral small carbohydrates through laser desorption/ionization time-of-flight mass spectrometry. Anal Chem. 2007;79:1626–33.CrossRefGoogle Scholar
  27. 27.
    Wang CW, Chen WT, Chang HT. Quantification of saccharides in honey samples through surface-assisted laser desorption/ionization mass spectrometry using HgTe nanostructures. J Am Soc Mass Spectrom. 2014;25:1247–52.CrossRefGoogle Scholar
  28. 28.
    Abdelhamid HN, Lin YC, Wu HF. Magnetic nanoparticle modified chitosan for surface enhanced laser desorption/ionization mass spectrometry of surfactants. RSC Adv. 2017;7:41585–92.CrossRefGoogle Scholar
  29. 29.
    Wang J, Jie M, Li H, Lin L, He Z, Wang S, et al. Gold nanoparticles modified porous silicon chip for SALDI-MS determination of glutathione in cells. Talanta. 2017;168:222–9.CrossRefGoogle Scholar
  30. 30.
    Juang YM, Chien HJ, Chen CJ, Lai CC. Graphene flakes enhance the detection of tio<inf>2</inf>-enriched catechins by SALDI-MS after microwave-assisted enrichment. Talanta. 2016;153:347–52.CrossRefGoogle Scholar
  31. 31.
    Guinan T, Ronci M, Vasani R, Kobus H, Voelcker NH. Comparison of the performance of different silicon-based saldi substrates for illicit drug detection. Talanta. 2015;132:494–502.CrossRefGoogle Scholar
  32. 32.
    Al-Hetlani E, Amin MO, Madkour M, Nazeer AA. Ceo<inf>2</inf>-cb nanocomposite as a novel SALDI substrate for enhancing the detection sensitivity of pharmaceutical drug molecules in beverage samples. Talanta. 2018;185:439–45.CrossRefGoogle Scholar
  33. 33.
    Cheng YH, Zhang Y, Chau SL, Lai SKM, Tang HW, Ng KM. Enhancement of image contrast, stability, and SALDI-MS detection sensitivity for latent fingerprint analysis by tuning the composition of silver-gold nanoalloys. ACS Appl Mater Interfaces. 2016;8:29668–75.CrossRefGoogle Scholar
  34. 34.
    Sangsuwan A, Narupai B, Sae-Ung P, Rodtamai S, Rodthongkum N, Hoven VP. Patterned poly(acrylic acid) brushes containing gold nanoparticles for peptide detection by surface-assisted laser desorption/ionization mass spectrometry. Anal Chem. 2015;87:10738–46.CrossRefGoogle Scholar
  35. 35.
    Kailasa SK, Wu HF. One-pot synthesis of dopamine dithiocarbamate functionalized gold nanoparticles for quantitative analysis of small molecules and phosphopeptides in SALDI- and MALDI-MS. Analyst. 2012;137:1629–38.CrossRefGoogle Scholar
  36. 36.
    Kurita M, Arakawa R, Kawasaki H. Silver nanoparticle functionalized glass fibers for combined surface-enhanced raman scattering spectroscopy (SERS)/surface-assisted laser desorption/ionization (SALDI) mass spectrometry via plasmonic/thermal hot spots. Analyst. 2016;141:5835–41.CrossRefGoogle Scholar
  37. 37.
    Lim AY, Ma J, Boey YCF. Development of nanomaterials for SALDI-MS analysis in forensics. Adv Mater. 2012;24:4211–6.CrossRefGoogle Scholar
  38. 38.
    Hong M, Xu L, Wang F, Geng Z, Li H, Wang H, et al. A direct assay of carboxyl-containing small molecules by saldi-ms on a AgNP/rGO-based nanoporous hybrid film. Analyst. 2016;141:2712–26.CrossRefGoogle Scholar
  39. 39.
    Duan J, Wang H, Cheng Q. On-plate desalting and SALDI-MS analysis of peptides with hydrophobic silicate nanofilms on a gold substrate. Anal Chem. 2010;82:9211–20.CrossRefGoogle Scholar
  40. 40.
    Kuo T-R, Wang D-Y, Chiu Y-C, Yeh Y-C, Chen W-T, Chen C-H, et al. Layer-by-layer thin film of reduced graphene oxide and gold nanoparticles as an effective sample plate in laser-induced desorption/ionization mass spectrometry. Anal Chim Acta. 2014;809:97–103.CrossRefGoogle Scholar
  41. 41.
    Li X, Xu G, Zhang H, Liu S, Niu H, Peng J, et al. A homogeneous carbon nanosphere film-spot: for highly efficient laser desorption/ionization of small biomolecules. Carbon. 2017;121:343–52.CrossRefGoogle Scholar
  42. 42.
    Lee G, Bae SE, Huh S, Cha S. Graphene oxide embedded sol-gel (GOSG) film as a SALDI MS substrate for robust metabolite fingerprinting. RSC Adv. 2015;5:56455–9.CrossRefGoogle Scholar
  43. 43.
    Grzelczak M, Vermant J, Furst EM, Liz-Marzan LM. Directed self-assembly of nanoparticles. ACS Nano. 2010;4:3591–605.CrossRefGoogle Scholar
  44. 44.
    Tao A, Sinsermsuksakul P, Yang P. Tunable plasmonic lattices of silver nanocrystals. Nat Nanotechnol. 2007;2:435–40.CrossRefGoogle Scholar
  45. 45.
    Kuo T-R, Chen Y-C, Wang C-I, Shen T-H, Wang H-Y, Pan X-Y, et al. Highly oriented Langmuir–Blodgett film of silver cuboctahedra as an effective matrix-free sample plate for surface-assisted laser desorption/ionization mass spectrometry. Nanoscale. 2017;9:11119–25.CrossRefGoogle Scholar
  46. 46.
    Inoue H, Moritani K, Date Y, Kohashi K, Tsuruta Y. Determination of free hydroxyproline and proline in human serum by high-performance liquid chromatography using 4-(5, 6-dimethoxy-2-phthalimidinyl) phenylsulfonyl chloride as a pre-column fluorescent labelling reagent. Analyst. 1995;120:1141–5.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Graduate Institute of Nanomedicine and Medical Engineering, College of Biomedical EngineeringTaipei Medical UniversityTaipeiTaiwan
  2. 2.School of Biomedical Engineering, College of Biomedical Engineering, School of Medicine, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  3. 3.Department of Orthopedics, Shuang Ho HospitalTaipei Medical UniversityNew Taipei CityTaiwan
  4. 4.Department of ChemistryTunghai UniversityTaichungTaiwan
  5. 5.Department of Applied ScienceNational Taitung UniversityTaitungTaiwan
  6. 6.International Ph.D. Program in Biomedical Engineering, College of Biomedical EngineeringTaipei Medical UniversityTaipeiTaiwan

Personalised recommendations